Sign In
Buy ENVB
$1.98
-0.240 (-10.81%)
At Close: Jun 03, 2026
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
08:30am, Thursday, 26'th Sep 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecul
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
08:30am, Wednesday, 25'th Sep 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecul
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
05:30pm, Monday, 12'th Aug 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecul
Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?
07:43am, Tuesday, 30'th Jul 2024
Enveric Biosciences (NASDAQ: ENVB ) stock is heading higher on Tuesday alongside heavy pre-market trading of the biotechnology company's shares. This comes with more than 13 million shares of ENVB s
Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)
08:00am, Friday, 28'th Jun 2024
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Bioscience
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
08:00am, Tuesday, 25'th Jun 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecul
Enveric Biosciences to Participate in BIO International Convention 2024
08:00am, Thursday, 30'th May 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecul
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
06:00am, Wednesday, 15'th May 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecul
MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic compounds VANCOUVER, BC / ACCESSWIRE /
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecul
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment
Enveric Biosciences, Inc. (ENVB) Stock Falls Amid Market Uptick: What Investors Need to Know
06:51pm, Thursday, 02'nd May 2024
The latest trading day saw Enveric Biosciences, Inc. (ENVB) settling at $0.93, representing a -0.46% change from its previous close.
Enveric Biosciences, Inc. (ENVB) Stock Declines While Market Improves: Some Information for Investors
06:56pm, Friday, 26'th Apr 2024
Enveric Biosciences, Inc. (ENVB) closed the most recent trading day at $0.90, moving -0.56% from the previous trading session.
New Strong Buy Stocks for April 17th
08:30am, Wednesday, 17'th Apr 2024
BYRN, YMAB, SAND, CORT and ENVB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
What Makes Enveric Biosciences (ENVB) a New Strong Buy Stock
01:01pm, Friday, 12'th Apr 2024
Enveric Biosciences (ENVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
